Reduction Of Proteinuria In Patients With Diabetes Mellitus Type 2 With Empagliflozin Treatment
Actual Nephrology · 2020
DOI: 10.14748/an.v14i1.7197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Actual Nephrology, 2020. Verfasst von Anton Dinkov und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Empagliflozin belongs to the group of SGLT2 inhibitors, which are a new class of glucose lowering agents. Through their unique mechanism to reduce sodium and glucose reabsorption through the proximal tubule, SGLT2 inhibitors play an important role in the prevention and treatment of diabetic nephropathy. The study included 8 patients with type 2 diabetes mellitus on empagliflozin therapy. All of them had their first morning urine albumin/creatinine ratios examined at the beginning and at the third month of treatment. The results showed a significant decrease in albuminuria in 6 of the patients by the third month after applying empagliflozin.
Zitieren
APA
Dinkov, A., & Kanazirev, B. (2020). Reduction Of Proteinuria In Patients With Diabetes Mellitus Type 2 With Empagliflozin Treatment. Actual Nephrology. https://doi.org/10.14748/an.v14i1.7197
Vancouver
Dinkov A, Kanazirev B. Reduction Of Proteinuria In Patients With Diabetes Mellitus Type 2 With Empagliflozin Treatment. Actual Nephrology. 2020. doi:10.14748/an.v14i1.7197
BibTeX
@article{Dinkov2020,
author = {Dinkov, Anton and Kanazirev, Branimir},
title = {Reduction Of Proteinuria In Patients With Diabetes Mellitus Type 2 With Empagliflozin Treatment},
journal = {Actual Nephrology},
year = {2020},
doi = {10.14748/an.v14i1.7197}
}
EUVIMED